The Bredesen Protocol™ – Is nutrition the key to Alzheimer’s?

Following our recent visit to the US, and The Buck Institute, we at Cytoplan are excited to announce a collaboration with Professor Bredesen – and The Bredesen Protocol™ – to help bring his work surrounding Alzheimer’s to the UK. The Bredesen Protocol™, a multi-factorial lifestyle and nutrition based approach to treating, and reversing, early onset Alzheimer’s, has so far successfully reversed Alzheimer’s symptoms in 90% of 110 people.

In this week’s blog we look at The Bredesen Protocol™ in more depth, the scale of the concern surrounding Alzheimer’s disease and the failings of monotherapy.

Reversal of cognitive decline – Diet and lifestyle intervention

From the moment we first saw publication of Professor Bredesen’s research paper ‘Reversal of cognitive Decline; a novel therapeutic programme’ in October 2014, and realised the programme involved almost exclusively diet and lifestyle intervention, it was something that excited us greatly.

Why? – because for 25 years we (at Cytoplan) have promoted a philosophy that diet and lifestyle errors are at the heart of most chronic diseases, and conversely if we can adopt a diet and lifestyle that gives our genes the nourishment and environment they need for health, most chronic diseases would no longer be.

It was particularly exciting to see Professor Bredesen’s work demonstrate that a disease such as Alzheimer’s – which is presently viewed as one which cannot be treated, prevented or reversed and is inciting such widespread fear among the population – is indeed not omnipotent and in fact is far more dynamic than popular medical opinion leads us to believe.

Cytoplan are in collaboration with Professor Bredesen and MPI Cognition, and he will be visiting the UK this Autumn to provide a talk surrounding the ongoing work of MPI Cognition and The Bredesen Protocol™.

To find out more about this event please follow the link.

Alzheimer’s disease – The Scale of the Problem

Alzheimer’s disease is reaching epidemic proportions and has ‘touched’ most of us through friends and family who suffer, or have died, from the disease. It is a growing problem that has recently been brought to the fore by many world leaders.

30 million people are affected globally (likely to be 160 million by 2050); it is the 3rd leading cause of death in USA and the leading cause of death for women in England and Wales (2nd for men).

 The Failure of Drugs & Monotherapy

Drug therapy and monotherapies (single agent drug therapy) for neurodegenerative diseases have failed, hundreds of £millions have been spent worldwide on drugs research and there is presently no effective treatment for Alzheimer’s disease as a result.

This failure is perhaps best explained by recent genetic and biochemical research, which has revealed an extensive network of molecular interactions involved in the pathogenesis of Alzheimer’s disease. Hence a network approach, rather than a single target drug approach, is likely to be more appropriate.

Dozens of biological mechanisms need to be brought into a state where they are enhancing a person’s cognitive health. There is a not a single therapy that exerts anything beyond a marginal, unsustained, symptomatic effect with little or no effect on disease progression. Complexity is therefore the main obstacle with Alzheimer’s disease and the people who have this condition.

Professor Bredesen likens this to a roof with many holes. Monotherapy (single agent drug therapy) plugs just one of these holes and one needs to plug a good number of the holes to have any chance of improving the condition. This latter approach utilised in the Bredesen Protocol™ programme equates to a multiple therapeutic approach, identifying and addressing the areas of imbalance.

Professor Bredesen hypothesises that Alzheimer’s disease, considered by much of medical science to be a single disease, actually consists of three distinct sub-types:

  • Inflammatory – in which markers such as C-reactive protein and serum albumin to globulin ratios are increased. These people have biomarkers of systemic inflammation.
  • Non-inflammatory – in which these markers are not increased but other metabolic abnormalities are present. This sub-type is known as ‘cold alzheimer’s’ and is often associated with low levels of vitamin D and high homocysteine.
  • Cortical/distinctly different – affects mainly young individuals and appears more widely distributed across the brain than the other subtypes of Alzheimer’s. Sufferers of this sub-type are always deficient in zinc – often toxic.

 Enter The Bredesen Protocol

Recently the first success in reversing cognitive decline in early Alzheimer’s disease and its precursors, [Mild Cognitive Impairment] MCI and [Subjective Cognitive Impairment] SCI, was reported (Impact Aging, Bredesen 2014).  This published study reported the initial 10 patients treated with a novel, therapeutic approach called The Bredesen Protocol™.

“Of the first ten patients tested, nine showed subjective or objective improvement. These included people with memory loss associated with Alzheimer’s disease and/or varying degrees of cognitive impairment. All six patients who had given up or severely limited work, returned to work or were able to work without difficulty.

And now over 100 patients have been treated, with unprecedented results. A clinical trial is planned in the USA and UK.

What is the Bredesen Protocol?

The Bredesen Protocol™ targets the multiple underlying causes of Alzheimer’s disease, with a goal to improve cognitive function.  The list below outlines the targets of the programme and the physiological biomarkers that it aims to change to improve cognition.

It simultaneously addresses:

  • Insoluble and soluble beta-amyloid
  • Tau and tau tangles
  • Metabolic issues
  • Inflammation
  • Toxicity
  • Insufficiency of trophic factors
  • Hormone imbalance
  • Gut health
  • Genetic errors
  • Nutrient deficiencies
  • Cognitive stimulation
  • Lifestyle factors that contribute to the pathology such as poor sleep; stress; lack of exercise; poor diet high in sugar

The same programme can be used by healthy individuals wanting to prevent Alzheimer’s disease and, as Professor Bredesen discovered, it seems to be a protocol that will optimise every area of health.

This is no surprise, really, because it comprises all areas of diet and lifestyle that the human genome needs for optimal health.

Most of the chronic diseases we see today are caused by a mismatch in the diet and lifestyle our genes need for health and the one in which we choose to adopt. We are effectively “fish out of water.”

 This situation can only really be remedied by understanding and meeting our genetic needs within our current environment – which is exactly what The Bredesen Protocol™ achieves.

Moreover it permits for individualisation. We humans are all genetically different in the same way as we look different on the outside. We know that “one man’s meat is another man’s poison,” and this exists because variations in genes that impact on metabolic processes dictate this.

For example, some people can drink large quantities of alcohol and recover well whilst others experience long-term effects from very small quantities. In the main this is due to differences in genetic detoxification and methylation pathways.

The science-based conclusions of Professor Bredesen in respect of Alzheimer’s disease include:

  • Monotherapy has never worked because Alzheimer’s disease is a condition of multiple aetiology affecting multiple pathogenetic and signalling pathways.
  • Alzheimer’s disease involves multiple patho-aetiology that is influenced by both intrinsic and extrinsic factors.
  • Alzheimer’s disease is wholly preventable and modifiable up until the late stages of disease.
  • Nutrition and lifestyle components are at the heart of the Bredesen Protocol™.
  • Inflammation drives metabolism dysfunction. Metabolic dysfunction is at the heart of Alzheimer’s disease.

The Bredesen™ Protocol & Cytoplan

bredesen

Since the  publication of Professor Bredesen’s paper on the subject of reversal of cognitive decline using the ‘MEND’ programme (‘metabolic enhancement for neurodegeneration’, now termed ‘The Bredesen Protocol™’), and his subsequent talk in the UK (March 2015), Cytoplan has been in close contact with Professor Bredesen and his team to try and bring the protocol and research to the UK.

Following our recent visit to the US, and the Buck Institute, we are excited to bring you the news that Professor Bredesen will be in England this September, and that he will be giving a talk on behalf of Cytoplan Education on September 8th.

Clinical trials are planned for the US and UK, and health practitioners and their patients are being sought to collaborate on this project.

We are also working with Dr Rangan Chatterjee* in the UK (well-known for his ‘prime time’ BBC series ‘Doctor in the House’) who will be trained by Professor Bredesen and mentored by him to use the The Bredesen Protocol™ with patients and the research subjects.

Dr Chatterjee will then head The Bredesen Protocol™ programme in the UK in the role of lead clinician, leading a team of doctors and heading the research to raise educate and raise public awareness on preventing early onset Alzheimer’s disease.

Summary

The most important thing to come out of Professor Bredesen’s research is that Alzheimer’s disease is not an omnipotent neurological disorder over which we have no control, but a metabolic disease which is wholly within our control. This is true right up to the late stages of the disease – which is another factor that underpins the importance of early diagnosis.

With this knowledge we can all be self-empowered about our health, not only for Alzheimer’s disease, but for many other chronic diseases too, as similarities have been identified between the disease process in Alzheimer’s disease and other diseases, such as Cancer, Osteoporosis, Atherosclerosis and Parkinson’s.


 Professor Dale Bredesen

A neurologist and Director, Easton Laboratories for Neurodegenerative Disease Research at DaleBredesenUCLA, Professor Bredesen trained with Nobel laureate Prof. Stanley Prusiner, and has published over 200 papers focused on the mechanisms and treatment of neurodegenerative disease. He is the founding President of the Buck Institute for Research on Aging in California.

Professor Bredesen has spent over 30 years researching the treatment and prevention of Alzheimer’s disease and is an acknowledged leader in the field of Alzheimer’s research, utilizing therapeutics rather than outmoded mono-therapeutics.


A Cytoplan Education Event – Thursday 8th September, 10.00am – 5.00pm.

CAM Conference Centre, 22 Duchess Mews, London, W1G 9DT

Alzheimers's image

Professor Bredesen will be speaking at our Cytoplan Education Event on 8th September on the scientific basis and unprecedented clinical results of The Bredesen Protocol™.

Dr Rangan Chatterjee (well-known for his ‘prime time’ BBC series ‘Doctor in the House’)  will speak about his role as lead clinician for The Bredesen Protocol™ in the UK, heading a team of doctors, nutritional and lifestyle therapists and the pre-clinical research. 

To find out more, and to book your place, please click here.


If you have any questions regarding the health topics raised in this article then please do get in touch via phone (01684 310099) or e-mail (amanda@cytoplan.co.uk)

Amanda Williams & The Cytoplan Editorial Team: Joseph Forsyth, Clare Daley and Simon Holdcroft


Relevant blogs

“Greeting from both myself and my Microbiome” – Dr Rangan Chatterjee

Dr Rangan Chatterjee – A talk on ‘Good Gut Health’

Could Alzheimer’s disease be ‘Type 3 Diabetes’?

Alzheimer’s and Dementia – Time for ‘A Novel Therapeutic Programme’?


Facebooktwittergoogle_pluslinkedinmail

29 thoughts on “The Bredesen Protocol™ – Is nutrition the key to Alzheimer’s?

  1. Really fascinating. I haven’t come across alzhemic clients yet but the fact that the protocol is assisting all chronic disease is marvellous news.

  2. The Bresden Protocol sounds interesting but WHAT IS IT? You have left us with a carrot dangling in front of our noses. How can we find out more?

    1. Hi Erica,

      The Bredesen Protocol™ is a comprehensive, personalised programme that targets the multiple underlying causes of Alzheimer’s disease, with an overall goal of improving cognitive function. The programme is able to identify all the biochemical and metabolic imbalances in an individual that give rise to the disease, and offers a tailored protocol to restore health and reverse the disease pathology.

      The paper ‘Reversal of cognitive decline: A novel therapeutic program’ (a link to which we provide in the blog) detailing the Bredesen Protocol™ is the first to suggest that memory loss in patients may be reversed – and improvement sustained – by using this 36-point therapeutic system that involves a comprehensive combination therapy approach combining medical expertise with software management to evaluate results and individualise the programme for each person. This paper openly details the science surrounding the protocol in a lot more depth – including recording successful patient case studies. A further paper is also soon to be published.

      The programme takes into account an individual’s genetic, metabolic, hormonal, and behavioural makeup to produce a personalised therapeutic program that is based on the underlying pathogenesis of Alzheimer’s disease, and which involves multiple modalities in the treatment protocol; including diet, supplements, exercise, sleep and other lifestyle changes – we will be going into more depth on the specific elements of the protocol in various blogs over the next few months.

      If you follow the link to another blog of ours – Alzheimer’s and Dementia – Time for ‘A Novel Therapeutic Programme’? – then towards the bottom you will find a number of useful links providing further research, blogs and articles concerning the science surrounding The Bredesen Protocol. You can also find more information on the MPI Cognition Website – the company responsible for leading The Bredesen Protocol ™ in the US.

      As a company we are investing large sums of money (as are our charitable owners – The AIM Foundation) to help bring this protocol to the UK; by helping to fund further research, set up clinics dedicated to the protocol in the UK, and simply raising awareness.

      If you have any further questions, please do not hesitate to contact me directly (amanda@cytoplan.co.uk).

      All the best,
      Amanda

        1. Hi Deb,

          Thank you for your comment on our blog and yes, they are currently updating their website.
          Have you seen the latest Bredesen news? Professor Bredesen spoke to NBC and the Today Show in America last week about his extensive research and protocol to fight against Alzheimer’s disease. You read the full article and watch the video via this link: http://www.today.com/health/new-brain-program-may-fight-alzheimer-s-t104636?platform=hootsuite

          Thanks,
          Amanda

  3. Hi, its amazing and exciting! Its the same what T. Colin Cambell said in “China Study” that all the common diseases, like cancer, Alzheimer’s, etc with different names have the same source and causes.

  4. What is The Bredesen Protocol? What nutrients etc? Surely one can’t be bound to attending a lecture to find out? Don’t you have product to see?

    1. Hi Janine,

      The Bredesen Protocol™ is a comprehensive, personalised programme that targets the multiple underlying causes of Alzheimer’s disease, with an overall goal of improving cognitive function. The programme is able to identify all the biochemical and metabolic imbalances in an individual that give rise to the disease, and offers a tailored protocol to restore health and reverse the disease pathology.

      The paper ‘Reversal of cognitive decline: A novel therapeutic program’ (a link to which we provide in the blog) detailing the Bredesen Protocol™ is the first to suggest that memory loss in patients may be reversed – and improvement sustained – by using this 36-point therapeutic system that involves a comprehensive combination therapy approach combining medical expertise with software management to evaluate results and individualise the programme for each person. This paper openly details the science surrounding the protocol in a lot more depth – including recording successful patient case studies. A further paper is also soon to be published.

      The programme takes into account an individual’s genetic, metabolic, hormonal, and behavioural makeup to produce a personalised therapeutic program that is based on the underlying pathogenesis of Alzheimer’s disease, and which involves multiple modalities in the treatment protocol; including diet, supplements, exercise, sleep and other lifestyle changes – we will be going into more depth on the specific elements of the protocol in various blogs over the next few months.

      If you follow the link to another blog of ours – Alzheimer’s and Dementia – Time for ‘A Novel Therapeutic Programme’? – then towards the bottom you will find a number of useful links providing further research, blogs and articles concerning the science surrounding The Bredesen Protocol. You can also find more information on the MPI Cognition Website – the company responsible for leading The Bredesen Protocol ™ in the US.

      As a company we are investing large sums of money (as are our charitable owners – The AIM Foundation) to help bring this protocol to the UK; by helping to fund further research, set up clinics dedicated to the protocol in the UK, and simply raising awareness.

      If you have any further questions, please do not hesitate to contact me directly (amanda@cytoplan.co.uk).

      All the best,
      Amanda

  5. very interesting need more detail on treatment and difference between alcheimers and dementia. thanks Dee Heath

    1. Hello Stephanie,

      Thank you for your interest in the Alzheimer’s clinical trial. If your husband could please email his contact details to Emma Williams (Emma@cytoplan.co.uk) she will pass them on to the clinical trial recruitment team and they will be in touch later in the year.

      All the best,
      Clare

  6. I am very impressed with the results of work of Dr. Bredesen’s team. It gives hope to many people, including me , who are aware of their ApoE4 carrier, and are bounded by the traditional medicine untill intensification of symptoms … This is the great chance for all of us…

  7. Hi I watched an interview with Dr Bredesen and am blown away iI have a mother who has dementia probably vascular as well as having had carbon monoxide poisoning so I have become very interested in all avenues of research about cognitive decline maybe a bit fearful of myself getting it as well. This seems to make the most sense of a personalized program and getting the different states of the body , biochemical and hormonal as well as ridding the body of toxin levels to optimum levels wow . What I was wondering is if it I could send this information to my moms treating physicians or would it be the wrong thing to do ethically ? We are in South Africa is there anything in the near future of running clinical trials here. This is such a breakthrough and I commend all who are working on thus I Thanks again

    1. Dear Mary Anne,

      Thank you for your comment on our blog. Yes I think it would be a good idea to send that information to your mother’s doctor. You could also forward a link to Professor Bredesen’s 2014 paper: https://www.ncbi.nlm.nih.gov/pubmed/25324467

      We will shortly be publishing an Action Against Alzheimer’s booklet which goes through diet and lifestyle steps that research has shown beneficial, particularly in the early stages. If you would like to email me your address: clare@cytoplan.co.uk, I will send you a copy. Also we do offer a free health questionnaire service that your mother may be interested in. If your mother completes and returns a health questionnaire we will send some written diet and supplement recommendations. Finally there will also be GP-led clinics in the UK in the future that will be able to consult with Alzheimer’s patients. I hope this information is useful to you. If you have any questions please contact me.

      Best wishes,
      Clare

      1. Hi Clare
        Thanks so much for getting back to me. I definitely would love the questionnaire for my mom and I will definitely send you my email details . I am going to let her physician in the know about prof Bredesen’ s paper too
        Regards Mary Anne

  8. That’s a very strong statement to make that you have reversed 90% 0f 110 people!
    Surely if that’s the case this would be world wide news and save on health budgets and save millions!
    As my wife of 59 has early onset Alzheimers I’m just a bit worried this is going to be a money making exercise out of a lot of people!

    1. Thank you for the comment on our blog,

      I do understand your concerns and reservations and I am so sorry to hear of your wife’s illness. Maybe I can explain a little more about Professor Bredesen’s work and the results of his protocol when used on people with active diagnosed Alzheimer’s disease.

      As I speak today, In the USA over 140 people with Alzheimer’s disease have used Professor Bredesen’s protocol, 90% of which have experienced a reversal of symptoms and returned to health sustainably. At this time there is further independent research planned in America, the UK and also Australia and we hope the results of this will prompt the health services to look more closely at how this protocol could be incorporated into mainstream medicine. As you are probably aware changing health policy is not a light decision and usually it requires research to be positive in many thousands of people and can be very expensive. Our charity are funding small scale research in the UK and we hope that along with the results of other similar research and the biochemical evidence that Professor Bredesen has able to demonstrate will provide the impetus for the NHS and/or other Alzheimer’s related funding bodies to start research on a larger scale.

      When I first saw Professor Bredesen’s research and studied the pathways he was describing, plus the evidence as to how the prescribed diet and lifestyle could impact beneficially on this disease process I was hugely excited as not only does its offer hope for sufferers, it also provides a very sound model that can be used by people wanting to help themselves prevent the disease and/or optimise their cognitive health. Since then I have met many of the people treated by Professor Bredesen and most of them have been able to return to work and are now once again leading normal lives, something that is not thought possible by mainstream UK medicine.

      After getting to know Dr Bredesen over the last 18 months I can tell you that his motivation is purely altruistic and he is personally driven to eradicate the global burden of Alzheimer’s disease.

      I would be very happy to talk to you in more detail as I do appreciate it may appear like a leap of faith whilst in fact it is a programme that is supported by research, biochemistry and scientifically validated evidence and one which is now being widely applied in the USA.

      Our dream would be to see it incorporated into the NHS so that the population at large could benefit.

      Please contact me directly should you have any further questions by emailing amanda@cytoplan.co.uk

      Thanks
      Amanda

    2. I would like to reassure people like Andrew that the protocol appears to be saving my husband’s life.

      He is 58 years old with a lost career and a PET scan to prove young Alzheimer’s. Almost since he started the Protocol he has slowly but surely started coming back to life. Even his driving has improved 🙂

      Today I saw our practice nurse for my own health needs and she looked at my name and without any prompting from me, commented that she had seen my husband last week about an ear infection. She said she had read in his notes that he had dementia. However she said she couldn’t reconcile the gap between the diagnosis and the man she had met.

      This youtube clip of Dr Breseden talking about is research is very helpful: https://www.youtube.com/watch?v=QqQ_X3mD16U

      I like to think that he might be nominated for a Nobel Prize in years to come. He will have earned it.

      1. Ive just watched it and I’m very impressed, what have I got to loose, or what has my wife got to loose. were do I sign up?

      2. just like to say thank you Stephanie for providing that link, what he said made so much sense, looking at the complete picture. As a builder I had to look at the complete picture and he’s right. Now I’m trying to find how to get on the Program and have e/mailed Amanda
        My wife has been on a trial drug for a year and bit and its just been pulled!
        Thanks again

        1. Andrew, we were both very moved by your comments, your wife’s story is gut-wrenching and she is fortunate to have you there to fight her corner. The protocol requires someone around to put it into place and given your job demands, we hope you have family members or friends around to co-opt to the cause as you will probably need their help. (We say this after watching our builders working on a diet of constant tea and biscuits over the summer!) We really hope you have extra support, if you want to think about beginning to do something now which will immediately benefit her, you could look at what a low GL diet will mean – dietdoctor.com/low-carb is a good place to start. we have heard that Cytoplan wants to set up a blog for participants in the protocol and the sooner this kicks off the better. Lots of good wishes from both of us, Stephanie and Tim

  9. We have just attended a talk in Hawick, Scotland by one of your practitioners presenting information about the Bredesen Protocol and we have a copy of your booket ‘Action Against Alzheimer’s Disease’ My husband is keen to take part in any proposed trial and wondered how we could take this forward as the results of previous studies seem very encouraging. Please advise,

    This is pioneering work from which a great many people could benefit and it is good to see Cytoplan so closely involved in this research.

    1. Dear Valerie
      Glad to hear you found Rosemary’s talk interesting. If you would like more information please email Emma@cytoplan.co.uk. The initial trial looks likely to be based in the Lancaster area. However it is possible that it will be replicated in other areas in the future.
      Best wishes
      Clare

We'd love your comments on this article
It's easy, just post your questions, comments or feedback below

Names will be displayed as entered. Your email address will not be published. Required *